Status:
UNKNOWN
Study to Re-assess and Re-confirm Data Previously Recorded About the Incidence and Severity of Acute Abdominal "Pancreatitis" Episodes in Lipoprotein Lipase Deficient (LPLD) Subjects Previously Enrolled on AMT Clinical Studies
Lead Sponsor:
Amsterdam Molecular Therapeutics
Collaborating Sponsors:
The Clinical Trial Company
Conditions:
Lipoprotein Lipase Deficiency
Eligibility:
All Genders
18-70 years
Brief Summary
Lipoprotein lipase deficiency (LPLD) is an autosomal recessive inherited condition caused by homozygosity or compound heterozygosity for mutations within the LPL gene. LPLD results in subjects present...
Detailed Description
Lipoprotein lipase deficiency (LPLD) is an autosomal recessive inherited condition caused by homozygosity or compound heterozygosity for mutations within the LPL gene. The most severe clinical compli...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Subjects must have participated in clinical studies study PREPARATION-02, CT-AMT-011-01 or CT-AMT-011-02,
Exclusion
Key Trial Info
Start Date :
November 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2016
Estimated Enrollment :
22 Patients enrolled
Trial Details
Trial ID
NCT01448577
Start Date
November 1 2010
End Date
March 1 2016
Last Update
October 7 2011
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
ECOGENE-21 Clinical Trial Center
Chicoutimi, Quebec, Canada, G7H 7P2
2
La Clinique de Maladies Lipidiques de Quebec Inc. (CMLQ, Inc.)
Québec, Quebec, Canada, G1V 4M6